Search
PDS Biotechnology Corp
PDSBAdd to Watchlist
0.231USD
-0.003-1.11%
Close 08-14 16:00（ET）Quotes delayed by 15 min
12.91MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of PDS Biotechnology Corp is 8.00, ranking 170 out of 387 in the Biotechnology & Medical Research industry. The average price target is 4.50, with a high of 15.00 and a low of 3.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
4.833
Target Price
+1995.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
PDS Biotechnology Corp
PDSB
3
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is PDS Biotechnology Corp's price target?
Analysts forecast that PDS Biotechnology Corp's price target is USD 4.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 3.00.
How have PDS Biotechnology CorpPDSB's recent earnings per share performed?
The market expectation was USD -0.18, while PDS Biotechnology CorpPDSB's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for PDS Biotechnology Corp?
Based on the ratings of PDS Biotechnology Corp's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.